Rahul Banerjee, MD, FACP, discusses key takeaways from his presentation at an OncLive State of the Science Summit on multiple myeloma. Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutch Cancer Center; member, the International Myeloma Working Group; assistant professor, Division of Hematology and Oncology, University of Washington, discusses key takeaways from the presentation he gave at an OncLive® State of the Science Summit™ on multiple myeloma, highlighting the disease’s evolving treatment paradigm.

Dr Banerjee on the Evolving Multiple Myeloma Treatment Paradigm

Taiga Nishihori, MD, discusses the findings from a study evaluating ciltacabtagene autoleucel given in the outpatient setting to patients with relapsed/refractory multiple myeloma. Taiga Nishihori, MD, senior member in the Blood & Marrow Transplant and Cellular Immunotherapy Department at Moffitt Cancer Center, discusses the findings from a single-center, retrospective study...

Outpatient Cilta-cel for Relapsed/Refractory Multiple Myeloma

Surgery isn’t a typical treatment for multiple myeloma. But in some cases, surgery may be necessary to address complications from the disease. Multiple myeloma is a rare type of cancer that causes abnormal cells to develop in your bone marrow. As multiple myeloma spreads, it can lead to bone damage or loss.

The Role of Surgery in Treating Multiple Myeloma

In an interview with Targeted Oncology, Richard Lee, MD, discussed what integrative oncology encompasses and its significance in modern cancer care. Integrative oncology is a growing field with the goal of improving cancer treatment through the incorporation of holistic approaches alongside conventional medical care. These therapies have also proved to be effective in reducing adverse effects like anxiety and depression in patients with cancer.1,2.

Enhancing Cancer Care With Integrative Oncology

Cancer Health

Intensive treatment near the end of life may not be the best option for people with very advanced cancer, according to study results reported in JAMA Oncology. Patients treated at oncology practices that frequently offer systemic therapy during the last two weeks of life did not have a survival advantage over those treated at practices that did so less often.

Reconsidering End-of-Life Treatment for People With Advanced Cancer

Thyroid cancer stages range from 1 to 4 (sometimes referred to in Roman numerals as I, II, III, and IV). Stage 4 thyroid cancer is the most serious; stage 1 is the least severe. The stage of someone's cancer is determined by the size and spread of cancer cells from a tumor's primary site, in this case, the thyroid gland.

What Are the Stages of Thyroid Cancer?

Researchers have demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy may improve progression-free survival in patients with oligometastatic pancreatic cancer, according to a recent study published by Ludmir et al in the Journal of Clinical Oncology and previously presented at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract 603). Background.

Metastasis-Directed Radiation Therapy Plus Chemotherapy in Oligometastatic Pancreatic Cancer

Dr. Qin Rao, an ABMS board certified internal medicine physician specializing in gastroenterology and hepatology, spoke with Healthline about when people with ulcerative colitis (UC) might consider biologic therapy to manage their condition. What are biologics, and how do they work for ulcerative colitis?. Biologics are medications, usually given as...

An Expert Explains When to Consider Biologics for Ulcerative Colitis (UC)

A second dendritic cell vaccine has received fast track designation from the Food and Drug Administration. The Food and Drug Administration (FDA) has granted a fast track designation to a dendritic cell vaccine for the treatment of patients with pancreatic ductal adenocarcinoma. Immuno-oncology company Diakonos Oncology Corporation announced the designation...

FDA Fast Tracks Pancreatic Cancer Vaccine

SurvivorNet

Discover new hope for refractory follicular lymphoma with FDA-approved Brukinsa and Gazyva. This groundbreaking treatment offers improved outcomes for patients who have exhausted other options.

Coping with Refractory Follicular Lymphoma: New Treatment On The Horizon

Everyday Health

Learn about eosinophilic esophagitis (EoE) and its symptoms, including chronic cough, treatment options, and diagnosis methods.

Can Eosinophilic Esophagitis Be the Reason Behind Your Chronic Cough?

MadameNoire

The recent study emphasizes the urgent need for advanced technologies to treat and potentially cure breast cancer.

Double Mastectomy Treatment May Not Increase Cancer Survival Rate, New Study Reveals

Tu Salud

People with type 2 diabetes who used glucagon-like peptide analogs such as Ozempic or Mounjaro had a lower risk for multiple types of cancer compared with those who used insulin, according to study results published in JAMA Network Open. Overweight and obesity have been linked to at least 13 types...

Weight-Loss Drugs May Prevent 10 Types of Cancer

In the phase II CUPISCO trial reported in The Lancet, Krämer et al found that molecularly guided therapy in patients with unfavorable nonsquamous cancer of unknown primary who had disease control on first-line platinum-based therapy resulted in better progression-free survival vs patients who continued chemotherapy. Study Details. In the...

Cancer of Unknown Primary: Molecularly Guided Therapy After Disease Control on Platinum-Based Chemotherapy

The FDA on Thursday signed off on Citius Pharmaceuticals’ Lymphir (denileukin diftitox-cxdl) for the treatment of patients with relapsed or refractory cutaneous T cell lymphoma, who have undergone at least one prior line of systemic therapy. Lymphir is Citius’ first FDA-approved product and currently the only treatment for cutaneous...

Citius Scores FDA Approval in Cutaneous T Cell Lymphoma

Study shows patients 80 years and older with atrial fibrillation treated with a lower dose of edoxaban experienced fewer major gastrointestinal bleeding events for each additional ischemic stroke. Patients aged 80 years and above with atrial fibrillation (AF) may gain a benefit from treatment with lower-dose anticoagulants regardless of existing...

Phase III Trial Shows Older Patients with Atrial Fibrillation May Benefit From Lower-Dose Anticoagulants

A panel of renal cell carcinoma experts deliberates on the treatment approach for a 59-year-old woman diagnosed with a left renal mass. EP: 2.Treatment Recommendations for a 59-Year-Old Woman with RCC.

Treatment Recommendations for a 59-Year-Old Woman with RCC

Following EHA 2024, an expert on hematologic malignancies provides key takeaways and reviews additional data updates on treatments for CLL/SLL. Video content above is prompted by the following question:. Are there any noteworthy key takeaways or additional data updates on CLL/SLL treatments discussed at EHA 2024 that you wish to...

Additional Data and Key Takeaways in CLL/SLL from EHA 2024

In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.

Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

Camden, NJ

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

Cornelius, NC

Morristown Minute

CAMDEN, N.J. – Lisa Smith, 61, of Cornelius, North Carolina, has admitted to her role in a fraudulent scheme involving over $3.5 million in Paycheck Protection Program (PPP) loans. U.S. Attorney Philip R. Sellinger announced today that Smith pleaded guilty before U.S. District Judge Karen M. Williams in Camden federal court on July 17, 2024, to a charge of bank fraud conspiracy.

Woman Pleads Guilty to $3.5M COVID Relief Scam

NewsBreak

Tailoring Regimens for Different Age Groups With Multiple Myeloma

During a Case-Based Roundtable® event, Andrew Yee, MD, discussed myeloma treatment strategies for different age groups, focusing on personalized regimens and the pros and cons of...

Tailoring Regimens for Different Age Groups With Multiple Myeloma

Comments / 0